Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Expected to Announce Earnings of $1.42 Per Share

Brokerages forecast that Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Rating) will post $1.42 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $1.25 to $1.75. Collegium Pharmaceutical reported earnings of $0.27 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 425.9%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Collegium Pharmaceutical will report full year earnings of $5.55 per share for the current financial year, with EPS estimates ranging from $4.81 to $6.48. For the next year, analysts expect that the company will report earnings of $6.74 per share, with EPS estimates ranging from $5.29 to $8.48. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLLGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.46). Collegium Pharmaceutical had a net margin of 15.68% and a return on equity of 3.26%. The business had revenue of $83.80 million during the quarter, compared to analysts’ expectations of $78.67 million. During the same period last year, the company earned $0.41 EPS. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis.

Several brokerages recently issued reports on COLL. Needham & Company LLC upped their price objective on shares of Collegium Pharmaceutical from $34.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, April 6th. Cantor Fitzgerald raised shares of Collegium Pharmaceutical from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $18.00 to $26.00 in a research note on Tuesday, February 15th. Piper Sandler upped their price objective on shares of Collegium Pharmaceutical from $36.00 to $42.00 and gave the company an “overweight” rating in a research note on Tuesday, February 22nd. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 26th. Finally, TheStreet downgraded shares of Collegium Pharmaceutical from a “b-” rating to a “c+” rating in a research note on Monday, April 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $31.00.

A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada increased its position in shares of Collegium Pharmaceutical by 126.3% in the first quarter. Royal Bank of Canada now owns 14,701 shares of the specialty pharmaceutical company’s stock worth $299,000 after acquiring an additional 8,206 shares in the last quarter. PDT Partners LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter worth $301,000. Captrust Financial Advisors increased its position in shares of Collegium Pharmaceutical by 97.5% in the first quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock worth $44,000 after acquiring an additional 1,062 shares in the last quarter. State Street Corp increased its position in shares of Collegium Pharmaceutical by 14.4% in the first quarter. State Street Corp now owns 1,308,167 shares of the specialty pharmaceutical company’s stock worth $26,634,000 after acquiring an additional 165,144 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Collegium Pharmaceutical by 1.1% in the first quarter. Invesco Ltd. now owns 1,010,612 shares of the specialty pharmaceutical company’s stock worth $20,576,000 after acquiring an additional 11,090 shares in the last quarter.

Shares of NASDAQ COLL traded up $0.38 on Friday, hitting $16.36. The company’s stock had a trading volume of 207,851 shares, compared to its average volume of 399,810. Collegium Pharmaceutical has a 12-month low of $14.04 and a 12-month high of $25.66. The company has a market capitalization of $554.93 million, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 0.16 and a beta of 1.07. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.97 and a quick ratio of 0.76. The stock has a 50 day moving average of $17.85 and a 200-day moving average of $18.49.

About Collegium Pharmaceutical (Get Rating)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Featured Articles

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.